AIA Group Ltd Raises Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Key Points

• AIA Group Ltd increased its stake in Alnylam Pharmaceuticals by 15.9% in the first quarter, adding 3,643 shares, bringing its total holdings to 26,491 shares valued at approximately $7.15 million.
• Alnylam Pharmaceuticals reported an EPS of $0.32 for the last quarter, outperforming expectations, and showing a 17.3% revenue increase year-over-year.
• Several analysts have raised their price targets for Alnylam stock, with Barclays setting a new target of $460 and Morgan Stanley increasing theirs to $405, indicating a positive outlook.

AIA Group Ltd boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 15.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,491 shares of the biopharmaceutical company's stock after acquiring an additional 3,643 shares during the quarter. AIA Group Ltd's holdings in Alnylam Pharmaceuticals were worth $7,153,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ALNY. Park Square Financial Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $28,000. Whipplewood Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 71 shares during the last quarter. Bessemer Group Inc. lifted its stake in Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 69 shares during the last quarter. Colonial Trust Co SC purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $35,000. Finally, Washington Trust Advisors Inc. lifted its stake in Alnylam Pharmaceuticals by 53.5% during the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock worth $47,000 after purchasing an additional 61 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Price Performance

ALNY stock traded up $10.21 on Thursday, reaching $442.73. 1,263,457 shares of the company's stock were exchanged, compared to its average volume of 952,829. The stock has a fifty day moving average of $339.44 and a 200-day moving average of $287.99. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $445.20. The firm has a market cap of $58.03 billion, a PE ratio of -179.24 and a beta of 0.25. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. The firm had revenue of $773,689 billion for the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%. Alnylam Pharmaceuticals's quarterly revenue was up 17.3% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.13) earnings per share. As a group, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ALNY shares. Wolfe Research upgraded Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a research note on Monday, August 4th. Wells Fargo & Company boosted their target price on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Wall Street Zen raised Alnylam Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Scotiabank lifted their price target on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a "sector outperform" rating in a research report on Friday, August 1st. Finally, Chardan Capital lifted their price target on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Four investment analysts have rated the stock with a hold rating, twenty-three have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $403.92.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of the business's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the sale, the chief executive officer directly owned 48,948 shares in the company, valued at approximately $14,978,088. The trade was a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.